Companies · Biotechnology

Novopyxis Inc.

Cambridge · Biotechnology

Diligence memoA one-page analyst read on Novopyxis Inc. — recommendation, valuation, rhythm, risks.
$856K
Total raised · real
2
Rounds
1.5×
Latest step-up
Top 85%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Mon Apr 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Novopyxis Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.34× the median modeled value of Pre-Seed Biotechnology companies in 2016–2018 (152 peers) — value vs value, same stage and era.
  • Within the normal band (134% of peer median) for its niche.
Dormant
  • Last raise 9.2 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Novopyxis Inc. is one of 4293 Biotechnology companies tracked from Cambridge. By capital raised it ranks in the long tail (ahead of 16% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
19
Investors (latest)
2013
Year incorporated
2017-04-24
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2014-07-09 Raised $343K (real) Modeled valuation $19M (est)$343K$19MPre-Seed2014Pre-Seed · 2017-04-24 Raised $513K (real) Modeled valuation $28M (est)$513K$28MPre-Seed2017+$513KCumulative $856K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$343K · 2014
Pre-Seed extension$513K · 2017

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$28.3M
Base estimate est.
$274K
Conservative case
$321.1M
Upside case
$2.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $18.9M · 2014-07-092014Pre-Seed · modeled $28.3M · 2017-04-242017
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
6.0 yr
Elapsed time used
9.2 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
34 mo
Avg between rounds
$306K/yr
Capital velocity
12.0 yr
On record since
2014
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$856K
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 1.2× above median
This company$513K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.4× of median
This company$28.3M
Sector median$64.2M

Raised more than 16% of sector peers (real $). Modeled value above 34% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #49 of 152.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)New Vital Signs, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Cerebral Magnetics INC · Pre-Seed Raised $1.0M · modeled $55.2M (est)NutriBand Inc. · Pre-Seed Raised $1.2M · modeled $55.2M (est)Jivana Biotechnology Inc · Pre-Seed Raised $2.0M · modeled $55.2M (est)AnTolRx, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)US Biologic, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Zeta Biolongevity, Inc. · Pre-Seed Raised $995K · modeled $54.9M (est)ALRGN Bio, Inc. · Pre-Seed Raised $946K · modeled $52.2M (est)Cellsolutions Llc · Pre-Seed Raised $1.9M · modeled $49.7M (est)BioSurfaces, LLC · Pre-Seed Raised $900K · modeled $49.7M (est)Pique Therapeutics, Inc. · Pre-Seed Raised $1.4M · modeled $47.2M (est)Gradient Pharmaceuticals, Inc. · Pre-Seed Raised $850K · modeled $46.9M (est)Novopyxis Inc. (this company) Raised $856K · modeled $28.3M (est)Novopyxis Inc.
CompanyStageRaised · realValue · estvs peer med.
New Vital Signs, Inc.Pre-Seed$1.0M$55.2M2.61×
Cerebral Magnetics INCPre-Seed$1.0M$55.2M2.61×
NutriBand Inc.Pre-Seed$1.2M$55.2M2.61×
Jivana Biotechnology IncPre-Seed$2.0M$55.2M2.61×
AnTolRx, Inc.Pre-Seed$1.0M$55.2M2.61×
US Biologic, Inc.Pre-Seed$1.0M$55.2M2.61×
Zeta Biolongevity, Inc.Pre-Seed$995K$54.9M2.60×
ALRGN Bio, Inc.Pre-Seed$946K$52.2M2.47×
Cellsolutions LlcPre-Seed$1.9M$49.7M2.35×
BioSurfaces, LLCPre-Seed$900K$49.7M2.35×
Pique Therapeutics, Inc.Pre-Seed$1.4M$47.2M2.23×
Gradient Pharmaceuticals, Inc.Pre-Seed$850K$46.9M2.22×
Novopyxis Inc. this companyPre-Seed$856K$28.3M1.34×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$343K2014-07-09$1.9M$18.9M85%
Pre-Seed$513K2017-04-24$2.8M$28.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$343K2014-07-09
    • First recorded raise — entered as Pre-Seed.
    • 12 investors on this round.
  2. Pre-Seed$513K2017-04-24
    • Raised again after 34 mo — slower than the ~14 mo sector norm.
    • Round 1.5× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 504).
    • 19 investors on this round.
Intelligence
2020 ~Q1
Modeled next raise · ~34mo cadence
$767K
Modeled next size est.range $513K$1.2M
1.5×
Last step-up
$306K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Madhavi Gavini2 other2014-07
Raja Srinivas1 other2014-07
Daniel Vannoni2014-07
Registry & provenance

Novopyxis Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1613912
SEC CIK
2013
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Kiffik Biomedical, Inc.BiotechnologyPre-Seed$830K$21.4Msame sector · same stage
Hydrus USA, Inc.BiotechnologyPre-Seed$825K$24.0Msame sector · same stage
Epien Medical, Inc.BiotechnologyPre-Seed$900K$24.3Msame sector · same stage
Truminim International CorpBiotechnologyPre-Seed$811K$31.6Msame sector · same stage
Biostratum IncBiotechnologyPre-Seed$906K$33.1Msame sector · same stage
GeneTether, IncBiotechnologyPre-Seed$912K$34.9Msame sector · same stage
Cellular Logistics, Inc.BiotechnologyPre-Seed$803K$34.1Msame sector · same stage
Windmill Cardiovascular Systems IncBiotechnologyPre-Seed$920K$23.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Novo Biosciences, Inc.BiotechnologySeed$177.6M93%
Novoron Bioscience, Inc.BiotechnologySeries A$135.4M87%
NexImmune, Inc.BiotechnologySeries B$308.3M86%
NERx Biosciences, Inc.BiotechnologyPre-Seed$4.8M86%
New Equilibrium Biosciences, Inc.BiotechnologySeries A$256.6M85%
Nexeon Medsystems IncBiotechnologySeries B$46.2M85%
Newomics Inc.BiotechnologySeed$149.0M85%
Nativis, Inc.BiotechnologySeries A$16.3M85%
Frequently asked
How much funding has Novopyxis Inc. raised?
Novopyxis Inc. has raised approximately $856K in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Novopyxis Inc.'s estimated valuation?
Provath's modeled valuation for Novopyxis Inc. is approximately $28.3M (modeled range $274K–$321.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Novopyxis Inc. at?
Novopyxis Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Mon Apr 24.
What does Novopyxis Inc. do and where is it based?
Novopyxis Inc. operates in the Biotechnology sector, based in Cambridge.
Explore related

See where Novopyxis Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Novopyxis Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.